At Blueleaf, the combined company formed by NHG and Clinicare Supplies, we empower the success of care homes around the world through the passion of our people and smart solutions. Blueleaf provides one of the most comprehensive ranges of products and services - from consumables and equipment, to furniture and interior design.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

news image

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

news image

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More

INDUSTRIAL IMPACT

ALLOY THERAPEUTICS RAISES $42 MILLION SERIES D FINANCING TO ACCELERATE DISCOVERY TECHNOLOGY DEVELOPMENT ACROSS BIOLOGIC MODALITIES

Alloy Therapeutics, Inc. | October 04, 2022

news image

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership model...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

SANA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF SC291 IND APPLICATION

Sana Biotechnology | January 30, 2023

news image

Sana Biotechnology, Inc., a firm focused on producing and delivering engineered cells as medicines, recently announced that the FDA has approved the company's Investigational New Drug (IND) application to begin a first-in-human trial of SC291 in patients with different types of B-cell malignancies. SC291 is an allogeneic CAR T cell therapy that targets CD19. It is developed by Sana using its hypoimmune platform. The hypoimmune platform's objective is to overcome the allo...

Read More
news image

LIMINAL BIOSCIENCES EXPANDS R&D PIPELINE WITH NOVEL PRECLINICAL PROGRAM FOR EOSINOPHILIC-RELATED DISEASES

Liminal BioSciences Inc. | July 20, 2020

Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, wh...

Read More
news image

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More
news image

INDUSTRIAL IMPACT

ALLOY THERAPEUTICS RAISES $42 MILLION SERIES D FINANCING TO ACCELERATE DISCOVERY TECHNOLOGY DEVELOPMENT ACROSS BIOLOGIC MODALITIES

Alloy Therapeutics, Inc. | October 04, 2022

Alloy Therapeutics, a biotechnology ecosystem company, has closed $42 million in Series D financing led by its existing investors 8VC and Mubadala Capital and joined by return investors Thiel Capital, Presight Capital, Founders Fund, and other unnamed family offices and sovereign wealth funds. Alloy will use proceeds from the Series D financing to further support the drug discovery community with new pre-competitive drug discovery technologies in new biologic modalities and new partnership model...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

SANA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF SC291 IND APPLICATION

Sana Biotechnology | January 30, 2023

Sana Biotechnology, Inc., a firm focused on producing and delivering engineered cells as medicines, recently announced that the FDA has approved the company's Investigational New Drug (IND) application to begin a first-in-human trial of SC291 in patients with different types of B-cell malignancies. SC291 is an allogeneic CAR T cell therapy that targets CD19. It is developed by Sana using its hypoimmune platform. The hypoimmune platform's objective is to overcome the allo...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us